Sasika N V Dewage
Overview
Explore the profile of Sasika N V Dewage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perera U, Organ L, Royce S, Samuel C, Derseh H, Dewage S, et al.
Can Respir J
. 2023 Jan;
2023:1522593.
PMID: 36710924
Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by excessive deposition of extracellular matrix in the interstitial lung parenchyma, often manifested by dyspnea and progressive loss of lung function....
2.
Perera U, Derseh H, Dewage S, Stent A, Wijayarathna R, Snibson K
BMC Genomics
. 2021 Nov;
22(1):827.
PMID: 34789159
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibroproliferative disorder that has one of the poorest prognoses amongst interstitial lung diseases. Recently, the finding of aberrant expression levels of...
3.
Perera U, Organ L, Dewage S, Derseh H, Stent A, Snibson K
Can Respir J
. 2021 Apr;
2021:6683195.
PMID: 33828632
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease, characterized by progressive damage to the lung tissues. Apoptosis and endoplasmic reticulum stress (ER stress) in type II alveolar epithelial...
4.
Dewage S, Organ L, Koumoundouros E, Derseh H, Perera K, Samuel C, et al.
Exp Lung Res
. 2019 Nov;
45(9-10):310-322.
PMID: 31762329
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with unknown cause. While the drugs nintedanib and pirfenidone have been approved for the treatment of IPF, they only...